港股異動 | 君實生物漲近5%,臨牀數據顯示君實生物VV116治療新冠效果不輸Paxlovid
$君實生物(01877.HK)$今日股價走高。針對中國COVID-19患者開展的最新III期臨牀研究成果顯示,相比PAXLOVID,公司旗下新冠藥物VV116組的臨牀恢復時間更短,安全性方面的顧慮更少。截至發稿,君實生物漲7.34%,報40.95港元,成交額0.46億港元。
北京時間12月29日,全球權威期刊《新英格蘭醫學雜誌》在線發表了君實生物旗下的口服核苷類抗新型冠狀病毒藥物VV116對比PAXLOVID用於伴有進展爲重度包括死亡高風險因素的輕至中度新型冠狀病毒感染(COVID-19)患者早期治療的III期臨牀研究(NCT05341609)成果。這是NEJM發表的首箇中國自主研發的新冠創新藥臨牀試驗。結果顯示,研究主要終點達到設計的非劣效終點,相比PAXLOVID,VV116組的臨牀恢復時間更短,安全性方面的顧慮更少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.